|31st December 2020||Paul Edward Walker||222||Open or private sale||$141.28||$31,364.65|
|31st December 2020||David M Mott||2,158||Grant/award etc.||$10.86||$23,435.88|
|31st December 2020||Paul Edward Walker||1,499||Open or private sale||$139.88||$209,684.92|
|31st December 2020||Paul Edward Walker||33,302||Open or private sale||$140.48||$4,678,328.23|
|30th December 2020||Paul Edward Walker||7,144||Open or private sale||$143.07||$1,022,056.36|
|30th December 2020||Paul Edward Walker||25,109||Open or private sale||$141.78||$3,559,883.71|
|30th December 2020||Paul Edward Walker||34,931||Open or private sale||$141.31||$4,936,190.43|
|30th December 2020||Peter J Barris||5,229||Grant/award etc.||$0.00|
|30th December 2020||Paul Edward Walker||1,208||Open or private sale||$143.81||$173,722.24|
|14th December 2020||David M Mott||486||Other acquisition or disposition||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Regulus Therapeutics, Inc. is a biopharmaceutical company. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. The company is also developing a pipeline of preclinical drug product candidates in renal, hepatic, and central nervous systems diseases.